Sustained virological response with intravenous silibinin: individualized <scp>IFN</scp>‐free therapy via real‐time modelling of <scp>HCV</scp> kinetics

Abstract

We report, for the first time, the use of real-time mathematical modelling of HCV kinetics to individualize duration of IFN-free therapy and to empower a patient to participate in shared decision making regarding length of treatment. SIL-based individualized therapy provides a treatment option for patients who do not respond to or cannot receive other HCV agents and should be further validated.